Biogen registers first-in-human trial of BIIB147 in ALS, called HORIZON

Biogen posted one new ALS trial registration this week.

• "A Randomized, Double-Blind, Placebo-Controlled MAD Study With Open-Label Extension to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BIIB147 Administered Intrathecally to Adult Participants With ALS" (NCT07855211, HORIZON) is a Phase 1/2 study of BIIB147 in amyotrophic lateral sclerosis. The study is a first-in-human trial, meaning the study drug will be given to people for the very first time in this study.¹ It is listed as not yet recruiting, with an estimated enrollment of 69 participants¹ and an estimated start date of 2026-10-22¹.